Ligand Pharmaceuticals (LGND) EPS Estimated At $1.11; GENTING HONG KONG LTD. ORDINARY SHARES (GTHKF) Sellers Increased By 93.17% Their Shorts

April 24, 2018 - By Marie Mckinney

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Logo

Analysts expect Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report $1.11 EPS on May, 8.They anticipate $0.72 EPS change or 184.62% from last quarter’s $0.39 EPS. LGND’s profit would be $23.54M giving it 37.16 P/E if the $1.11 EPS is correct. After having $1.03 EPS previously, Ligand Pharmaceuticals Incorporated’s analysts see 7.77% EPS growth. The stock decreased 1.35% or $2.25 during the last trading session, reaching $164.97. About 48,886 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since April 24, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

GENTING HONG KONG LTD. ORDINARY SHARES (OTCMKTS:GTHKF) had an increase of 93.17% in short interest. GTHKF’s SI was 2.04M shares in April as released by FINRA. Its up 93.17% from 1.06 million shares previously. With 12,800 avg volume, 159 days are for GENTING HONG KONG LTD. ORDINARY SHARES (OTCMKTS:GTHKF)’s short sellers to cover GTHKF’s short positions. The SI to GENTING HONG KONG LTD. ORDINARY SHARES’s float is 0.1%. It closed at $0.19 lastly. It is down 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Since December 20, 2017, it had 0 insider purchases, and 12 selling transactions for $16.28 million activity. FOEHR MATTHEW W sold $832,824 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Friday, February 23. Sabba Stephen L sold $126,956 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, December 20. Davis Todd C sold $2.62 million worth of stock or 17,170 shares. 2,500 shares were sold by KOZARICH JOHN W, worth $401,063 on Monday, April 2. 9,000 shares were sold by HIGGINS JOHN L, worth $1.41 million. Aryeh Jason also sold $1.32 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares. Shares for $536,604 were sold by LAMATTINA JOHN L.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $3.50 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 311.26 P/E ratio. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Investors sentiment decreased to 1.25 in Q4 2017. Its down 0.44, from 1.69 in 2017Q3. It turned negative, as 21 investors sold Ligand Pharmaceuticals Incorporated shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. Dupont Cap has 12,462 shares for 0.04% of their portfolio. Gotham Asset Mngmt Lc stated it has 52,100 shares or 0.1% of all its holdings. Court Place Advsrs Ltd Liability Corp reported 19,914 shares. 48,837 were reported by Tygh Cap Mgmt. Baker Bros Advsr Limited Partnership reported 73,386 shares. Ami Asset reported 121,964 shares. First Republic invested in 0.01% or 5,756 shares. 6,732 are held by Envestnet Asset Management. Louisiana State Employees Retirement stated it has 9,100 shares. Granite Invest Partners stated it has 84,598 shares. D E Shaw And has invested 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Parallax Volatility Advisers Lp owns 8,101 shares for 0% of their portfolio. Dekabank Deutsche Girozentrale owns 9,770 shares. Strs Ohio has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 20,600 were reported by Quantitative Investment Mgmt Lc.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>